Trial Profile
Multicenter, Randomised, Double-blind Phase III Trial to Investigate the Efficacy and Safety of BIBF 1120 in Combination With Carboplatin and Paclitaxel Compared to Placebo Plus Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary) ; Carboplatin; Paclitaxel
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Registrational; Therapeutic Use
- Acronyms LUME-Ovar-1; OVAR12
- Sponsors Boehringer Ingelheim; Boehringer Ingelheim Pharma KG; Boehringer Ingelheim Pharmaceuticals
- 15 Jan 2020 Results published in the International Journal of Cancer
- 13 Jun 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 06 Jun 2017 Results (n=1355) of exploratory analysis assessing the prognostic value of tumor residuals, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology